SSRI antidepressant drug use patterns in the naturalistic setting: A multivariate analysis

Medical Care

Volumn 37, Issue 4 SUPPL. 1, 1999, Pages

  Hylan, Timothy R ^a,b   Crown, William H ^c   Meneades, Laurie ^c   Heiligenstein, John H ^a   Melfi, Catherine A ^a,d,e   Croghan, Thomas W ^a,d   Buesching, Don P ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MEDSTAT GROUP   (United States)

^d INDIANA UNIVERSITY   (United States)

^e REGENSTRIEF INSTITUTE   (United States)

Author keywords

Antidepressants; Depression; Drug use patterns; Selective serotonin reuptake inhibitors

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLASSIFICATION; COMPARATIVE STUDY; DEPRESSION; DRUG UTILIZATION; FACTUAL DATABASE; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; PATIENT CARE; PSYCHOTHERAPY; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ADULT; DATABASES, FACTUAL; DEPRESSIVE DISORDER; DRUG UTILIZATION; EPISODE OF CARE; FEMALE; FLUOXETINE; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PAROXETINE; PSYCHOTHERAPY; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; UNITED STATES;

EID: 0033111384     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199904001-00007     Document Type: Article

References (36)

1. Kasper S, Fuger J, Moller, HJ. Comparative efficacy of antidepressants. Drugs 1992;43:11.
2. Potter WZ, Rudorfer MV, Monji H. The pharmacologic treatment of depression. NEJM 1991;325:633.
3. Tollefson GD. Antidepressant treatment and side effect consideration. J Clin Psychiatr 1991;52:4.
4. Sturm R, Wells K. How can care for depression become more cost-effective? JAMA 1995;273(1):51.
5. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatr 1992;49(10):761.
6. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive disorder: How long should it be maintained? Am J Psychiatr 1986;143:18.
7. Montgomery SA. Prophylaxis in recurrent unipolar depression: A new indication for treatment studies. J Psychopharmacol 1989;3:47.
8. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: A prospective study. Am J Psychiatr 1992;149(6):795.
9. Altamura AC, Percudani M. The use of antidepressants for long-term treatment of recurrent depression: Rationale, current methodologies, and future direction. J Clin Psychiatr 1993;54(suppl 8):29.
10. Agency for Health Care Policy Research. Treatment of major depression: Clinical practice guidelines. No. 5, Vol. 2. Rockville, MD: US Department of Health and Human Services. AHCPR Publication no. 93-0550, 1993.
11. Thompson D, Buesching D, Gregor K, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Manage Care 1996;2(9):1239.
12. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value Health; in press.
13. Gregor K, Overhage M, Coons S, McDonald R. Selective serotonin reuptake inhibitor dose titration in a naturalistic setting. Clin Ther 1994;16(2):306.
14. Sclar DA, Robison LM, Skaer TL, Galin RS, Legg RF, Nemec NL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertaline in a health maintenance organization. J Int Med Res 1995;23:395.
15. Olufade AO, Gregor KJ, James SP. Efficacy vs. effectiveness: The generalizability of randomized controlled trials in depression. Int Clin Psychopharmacol 1999; in press.
16. Brooks JM, Dor A, Wong HS. Hospital-insurer bargaining: An empirical investigation of appendectomy pricing. J Health Econ 1997;16:417.
17. Frank RG, Salkever DS, Sharfstein SS. A new look at rising mental health insurance costs. Health Aff 1991;10:116.
18. Hillman AL, Schwarz JS, Willian MK, Feskin E, Claus G, et al. The Cost Effectiveness of Terazosin and Placebo in the Treatment of Moderate to Severe Benign Prostatic Hyperplasia. Urology 1996;47(2):169.
19. Topol EJ, Ellis SG, Cosgrove DM, Bates ER, Muller DW, et al. Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation 1993;87:1489.
20. Simon G, Von Korff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatr 1993;15(6):399.
21. Greene WH. Limdep. Vol. 7. New York: Econometric Software, 1995.
22. Roback G, Randolf L, Seidman B, eds. Physician characteristics and distribution in the United States. Chicago: American Medical Association, 1993.
23. International Classification of Diseases. 9th Revision, Clinical Modification, 1990.
24. Stokes PE. Ruoxetine: A five-year review. Clin Ther 1993;15:216.
25. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline vs. fluoxetine. J Clin Psychiatr 1995;56(7):288.
26. Lejoyeux M, Ades J, Mourad I, Solomon J, Disalver S. Antidepressant withdrawal syndrome: Recognition, prevention and management. CNS Drugs 1996;5(4):278.
27. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16(3):356.
28. Dunn RL, Donoghue JM, Ozminkowski RJ, Hylan TR. Selective serotonin reuptake inhibitor antidepressant prescribing in primary care in the United Kingdom. Primary Care Psychiatr 4(3):141.
29. Montejo AL, Gilaberte I, Fombellida C, Hylan TR, Sacristan JA. Patron de uso de los inhibidores de la recaptacion de serontonina y venlafaxina en la practica clinica, Actas Luso Espanolas de Neurologia y Psiquiatria 1998;26(2):75.
30. Rosenbaum J, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatr 1998;44:77.
31. Hylan TR, Crown WH, Meneades L, Heiligenstein JH, Melfi C, Croghan TW, et al. SSRI and TCA antidepressant selection and health care costs: A multivariate analyses. J Affective Disorders 1998;47:71.
32. Fairman KA. The doctor told me to cut the pills in half: Practical considerations in using claims databases for outcomes research. Drug Benefit Trends 1997;9(10):30.
33. Melfi CA, Chawla AJ, Croghan TW, Hanna M, Kennedy S, Sredl K. The effect of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatr 1998;55:1128.
34. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: Description and validation. Med Care 1988;26:814.
35. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997; 50(1):105.
36. Greenberg RN. Overview of patient compliance with medication dosing: A literature review. Clin Ther 1984;6(5):592.